Andrew Hill Investment Advisors Inc. Has $2.36 Million Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Andrew Hill Investment Advisors Inc. decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 36.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,761 shares of the medical equipment provider's stock after selling 2,730 shares during the quarter. Intuitive Surgical comprises approximately 2.3% of Andrew Hill Investment Advisors Inc.'s investment portfolio, making the stock its 19th biggest holding. Andrew Hill Investment Advisors Inc.'s holdings in Intuitive Surgical were worth $2,358,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ISRG. Burns J W & Co. Inc. NY grew its position in shares of Intuitive Surgical by 16.3% during the 1st quarter. Burns J W & Co. Inc. NY now owns 11,739 shares of the medical equipment provider's stock worth $5,814,000 after buying an additional 1,649 shares during the period. Rothschild Investment LLC increased its stake in Intuitive Surgical by 16.6% in the first quarter. Rothschild Investment LLC now owns 561 shares of the medical equipment provider's stock valued at $278,000 after purchasing an additional 80 shares in the last quarter. Global Financial Private Client LLC raised its holdings in Intuitive Surgical by 253.3% in the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 38 shares during the period. GoalVest Advisory LLC boosted its position in shares of Intuitive Surgical by 2,308.9% during the first quarter. GoalVest Advisory LLC now owns 2,963 shares of the medical equipment provider's stock worth $1,467,000 after purchasing an additional 2,840 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Intuitive Surgical by 54,010.7% in the 1st quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider's stock valued at $14,999,630,000 after buying an additional 3,022,979 shares during the period. 83.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on ISRG. Barclays cut their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Citigroup reiterated a "buy" rating and set a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. BTIG Research set a $560.00 price objective on shares of Intuitive Surgical and gave the company a "buy" rating in a report on Monday, April 14th. Piper Sandler lowered their target price on Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. Finally, Erste Group Bank downgraded Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a report on Monday, March 17th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $596.05.

Intuitive Surgical Price Performance

ISRG traded down $1.44 during trading on Tuesday, hitting $551.85. 1,713,465 shares of the stock traded hands, compared to its average volume of 1,644,487. The business has a 50 day moving average price of $517.32 and a 200 day moving average price of $538.73. Intuitive Surgical, Inc. has a twelve month low of $397.47 and a twelve month high of $616.00. The company has a market cap of $197.79 billion, a price-to-earnings ratio of 86.09, a PEG ratio of 5.85 and a beta of 1.70.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The company had revenue of $2.25 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same quarter last year, the company posted $1.50 EPS. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, Director Jami K. Nachtsheim sold 2,400 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the transaction, the director now directly owns 6,371 shares in the company, valued at approximately $3,312,920. This represents a 27.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Mark Brosius sold 492 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $554.17, for a total value of $272,651.64. Following the completion of the sale, the senior vice president now owns 3,072 shares of the company's stock, valued at $1,702,410.24. The trade was a 13.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 25,778 shares of company stock worth $12,867,197 over the last 90 days. Insiders own 0.70% of the company's stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.